Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.15), Zacks reports.
Acumen Pharmaceuticals Stock Performance
ABOS stock traded down $0.12 during midday trading on Monday, reaching $1.08. 217,734 shares of the company were exchanged, compared to its average volume of 288,623. Acumen Pharmaceuticals has a one year low of $1.07 and a one year high of $4.06. The firm has a market capitalization of $64.59 million, a price-to-earnings ratio of -0.77 and a beta of 0.02. The business has a 50-day moving average price of $1.38 and a two-hundred day moving average price of $1.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. HC Wainwright decreased their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating for the company in a research note on Friday. UBS Group lowered their price objective on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday.
View Our Latest Analysis on Acumen Pharmaceuticals
Insider Activity
In other Acumen Pharmaceuticals news, CFO Matt Zuga sold 28,902 shares of the company's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the transaction, the chief financial officer now directly owns 231,744 shares of the company's stock, valued at $398,599.68. This represents a 11.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total value of $87,911.52. Following the sale, the chief executive officer now directly owns 454,707 shares of the company's stock, valued at $836,660.88. This represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock valued at $233,124 over the last ninety days. 7.10% of the stock is currently owned by company insiders.
About Acumen Pharmaceuticals
(
Get Free Report)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
See Also
Before you consider Acumen Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.
While Acumen Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
